PAPER

Check for updates

Rapid detection of major Gram-positive pathogens in ocular specimens using a novel fluorescent vancomycin–based probe†

Richa Sharma, [iD] [a] Harinee Rajagopalan,[b] Maxime Klausen, [iD] [a] Mani Vimalin Jeyalatha,[b] Muhammed Üçüncü, [iD] [ac] Seshasailam Venkateswaran,[a] Appakkudal R. Anand*[b] and Mark Bradley [iD] *[a]

Bacterial infections of the eye are significant causes of morbidity that can lead to permanent visual loss without rapid and adequate treatment, with Gram-positive bacteria causing the majority of ocular infections. Here we report a novel probe, based on the reductive amination of vancomycin with a 4-nitrobenzoxadiazole (NBD)-based aldehyde, that rapidly and specifically detects Gram positive infections from ocular samples.

Introduction

Bacterial infections of the eye are significant causes of morbidity that can lead to permanent visual loss without rapid and adequate treatment.[1,2] Aetiological studies have shown that Gram-positive bacteria cause the majority of ocular infections.[1] Accurate information of the Gram status of the bacterial aetiology is critical to tailor appropriate antimicrobial therapy. Current rapid diagnosis of bacterial infection relies on observing the Gram-stained specimens by direct microscopy, which can provide information on the presence and type of bacteria. However, Gram staining generates a high rate of false negative results especially in ocular specimens where the sample volume is minimal. In order to increase sensitivity of detection of bacteria, isolation of the bacterium by microbial culture followed by identification is a commonly adopted procedure. This is considered the gold standard for laboratory diagnosis, although it may take many days for growth, delaying treatment. Hence, there is an urgent need to develop alternate rapid and accurate labelling techniques to detect and identify bacteria in clinical specimens[3] and a few studies have demonstrated the application of Gram-selective optical probes with clinical specimens.

Several strategies have been used to develop Gram-specific fluorescent probes,[4–7] including the development of positively charged dyes[8] or aggregation-induced emission systems,[9–12] or the direct covalent conjugation of known fluorophores to pathogen-binding ligands.[13–16] In this exploratory study, we designed and evaluated a fluorescent probe for the rapid detection of Gram-positive bacteria in ocular specimens in comparison with the conventional Gram stain.[17,18] The fluorescent probe developed (a vancomycin–NBD conjugate here called Van-Green) discriminated Gram-positive bacteria from other bacteria with excellent selectivity and vitally did not require any modification to the readily available microscope systems widely used in the laboratory. The optical molecular imaging agent used here, Van-Green, was designed with a solvato-fluorogenic dye[16] conjugated to the clinically approved glycopeptide antibiotic vancomycin. The design of the probe imitates the structure of oritavancin, a semi-synthetic vancomycin derivative in which the vancosamine moiety (*i.e.* the amino sugar) was modified with a bis-aryl group by reductive amination.[19,20] This modification dramatically improves biological activity[21,22] even on vancomycin-resistant strains of Gram-positive bacteria.[20,23] In the present design, a benzaldehyde derivative of the 4-nitrobenzoxadiazole (NBD) fluorophore (a bis-aryl type structure) was prepared and conjugated to vancomycin so as to take advantage of the same enhancement of binding effect. NBD, a well-described "environmentally-sensitive" green fluorophore,[24] emits in hydrophobic environments, and is non-fluorescent in aqueous solutions thus giving high signal-to-noise ratios without the need to wash-off excess of probe from the sample. In addition, NBD is a robust, oxygen insensitive and easily accessible dye, making the synthesis of this new probe quick and cost-efficient compared to other custom-made dyes.

[a] EaStCHEM, School of Chemistry, University of Edinburgh, King's Buildings, Edinburgh, EH9 3FJ, UK. E-mail: Mark.Bradley@ed.ac.uk
[b] L & T Microbiology Research Centre, Medical Research Foundation, Sankara Nethralaya, Chennai, India. E-mail: aranand@gmail.com
[c] Department of Analytical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d2sd00061j

Results and discussion

The benzaldehyde-modified NBD analogue (NBD-Bn-CHO) was synthesized in two steps starting from the commercially available dye precursor 4-chloro-7-nitrobenzofurazan (NBD-Cl). Nucleophilic aromatic substitution with p-(aminomethyl)benzylalcohol was followed by Dess–Martin periodinane (DMP) oxidation to afford the key aldehyde intermediate in a good, two-step, yield of 57%. The fluorophore was subsequently conjugated to the amino-sugar moiety of vancomycin using reductive amination, as previously described,[19] to give Van-Green after purification by reverse phase HPLC. This transformation was selective and orthogonal to all the other vancomycin functional groups, and gave access to the final probe in only 3 steps and on a 100 mg scale (Scheme 1).

Van-Green was fully characterized chemically (HPLC, HRMS and FTIR, Fig. S4 and S5†) and photophysically. In accordance with the optical properties of other NBD probes,[24] Van-Green had an excitation maximum around 480 nm and emitted in the green ($\approx$540 nm). In addition, the fluorescence intensity of the imaging agent proved to be sensitive to changes in the polarity of the environment, as demonstrated by the alteration of its brightness in PBS solutions containing different percentages of DMSO (Fig. 1). By determining ε and Φ_f values for each PBS/DMSO mixture (Table S1†), we found a progressive, 22-fold, increase in brightness ($\varepsilon\Phi_f$) in pure DMSO compared to aqueous buffers with negligible variations in excitation and emission wavelengths. This solvato-fluorogenic character is the key to labelling, selectively, pathogen membranes/cell walls without the need for washing steps,[16] as the low fluorescence in aqueous media reduces background signal and "lights-up" the bacteria.


Fig. 1 Top panel: Evolution of the fluorescence intensity and lower panel: brightness ($\varepsilon\Phi_f$) of solutions of Van-Green (5 μM) with increasing percentages of DMSO in PBS upon excitation at 475 nm.

Biological validation

Optimization of probe concentration. The optimisation of the probe concentration for imaging was initially performed on a *S. aureus* ATCC 29213 strain.

The probe showed good labelling of bacteria down to 0.1 μM for the target microbe (Fig. 2), which is lower than the reported minimum inhibitory concentration (MIC) of the parent vancomycin.[22] Intense fluorescence was observed for 5–100 μM probe, showing that the vancomycin ligand has strong affinity for the cell wall of Gram positive bacteria and the dye does not affect its binding.

Specificity of the probe. The applicability and specificity of the vancomycin-based probe was proven by the strong labelling of different Gram positive species (*S. aureus* ATCC 25923, *Streptococcus pyogenes* (ATCC 12384), *B. cereus* (ATCC 13061)) and negligible signals in the case of Gram negative bacilli: *Escherichia coli* DH5α, *Escherichia coli* (ATCC 25922) and *Pseudomonas aeruginosa* (ATCC 27853) (see Fig. 3 and S6†).

However, the intensity of staining of Gram positive bacteria differed, with *S. aureus* showing uniform bright fluorescence, while *B. cereus* showed irregular staining. Time for detection was <20 minutes similar to the time taken for

**Scheme 1** Synthetic route to the imaging agent Van-Green.

Fig. 2 Labelling of *S. aureus* ATCC 29213 by Van-Green (top panel: fluorescence; bottom panel: brightfield).

Fig. 3 (a) Intense labelling of *B. subtilis*, *S. pyogenes* and *S. aureus* by Van-Green; (b) negligible labelling of *E. coli* DH5α, *P. aeruginosa* ATCC 27853 and co-culture of *E. coli* DH5α and *S. aureus* ATCC 29213 cells by Van-Green 5 μM (top panel: fluorescence; lower panel: brightfield); (c) the comparison of fluorescence intensity (5 μM Van-Green) for target and non-target species as calculated by ImageJ, Fiji. Other controls represent wells with bacteria alone and probe alone.

Gram staining. When a mixture of Gram positive and Gram negative bacteria were stained, the probe specifically stained the Gram positive bacteria and Gram negative bacteria remained unstained (see Fig. 3 and S6†).

Antibacterial activity of the probe. To evaluate whether the fluorescent probe retained the antibiotic activity of the parent drug, the MICs were measured against representative Gram-positive (*S. aureus*) and Gram-negative (*E. coli*) bacterial strains. Standard broth microdilution assays were used for determination of MICs (see Experimental section). We observed that Van-Green did possess anti-bacterial activity against *S. aureus*, however, the probe's MICs against *S. aureus* was 4 μM (Fig. S8†) compared to <0.25 μM for vancomycin. Van-Green is therefore 16 times less potent than the parent antibiotic against Gram-positive bacteria. As expected, both Van-green and vancomycin showed no anti-bacterial activity against the Gram-negative bacterium tested (MIC > 64 μM). We also performed a live/dead bacterial staining experiment on Gram positive bacteria with the probe allowed to interact with bacteria for 60 minutes. The microbial cells showed no internalization of the

dye propidium iodide, signifying that, in the labelling period, the dye does not kill the bacteria (Fig. S9†).

Van-Green staining of ocular specimens. Specimens collected from patients (15 smear positive samples) were used for the validation of the probe and the results were compared with the Gram Stain results (Table 1).

The brightness of the staining was characterized as +++, ++, + and −. As shown in Table 1, all specimens that showed Gram positive (GP) bacteria by the traditional Gram stain and culture were also positive using the NBD (Van-Green) probe. Gram negative (GN) bacteria showed little or no staining.

There was complete concordance (100%) in specimens with Gram positive infections, namely, *Staphylococcus*, *Streptococcus*, *Actinomycetes* spp and *Corynebacterium* spp. In one sample where *Bacillus cereus* was seen and grown, the probe did stain the bacteria, but the staining was not uniform. Two specimens grew *P. aeruginosa* and two grew *Neisseria subflava* and *Klebsiella oxytoca* respectively, which did not take up the NBD stain indicating its selectivity for Gram-positive bacteria. Representative microscopy images are shown in Fig. 4 and S7.†

Experimental section

Materials

Standard microbiological strains. The efficacy of the probe was tested on Gram positive *Staphylococcus aureus* ATCC 29213 and ATCC 25923, *Streptococcus pyogenes* (ATCC 12384), *Bacillus cereus* (ATCC 13061) and Gram-negative *Escherichia coli* DH5α, *Escherichia coli* (ATCC 25922) and Gram-negative *Pseudomonas aeruginosa* (ATCC 27853).

Clinical specimens: included corneal scrapings (4), eviscerated material (4), canalicular pus (2), pus from eyelids (2), pus from the orbit (1), scleral scrapings (1) and aqueous humor (1).

Methods

Synthesis of NBD-Bn-OH. An aqueous solution of *p*-(aminomethyl) benzylalcohol (*p*AMBA, 350 mg, 2.57 mmol) in 0.3 M aqueous NaHCO$_3$ (10 mL) was added to a solution of 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl, 497 mg, 2.49 mmol) in MeOH (20 mL) and the reaction mixture was stirred overnight at room temperature. The title compound was obtained after purification by silica gel chromatography (hexane : EtOAc, 1 : 2, v/v) (orange solid, 464 mg, yield 60%).

^{1}H NMR (500 MHz, DMF-d_7) δ ppm: 8.51 (d, *J* = 8.9 Hz, 1H), 7.49 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 8.2 Hz, 2H), 6.49 (d, *J* = 8.9 Hz, 1H), 4.86 (s, 2H), 4.61 (s, 2H). ^{13}C NMR (126 MHz, DMF-d_7) δ ppm: 145.2, 144.9, 144.3, 142.1, 137.1, 135.5, 127.3, 126.6, 121.6, 99.6, 63.1, 46.7. HRMS (ESI)[+] calcd for C$_{14}$H$_{13}$N$_4$O$_4$ [M + H]$^+$ *m/z* 301.09313 found *m/z* 301.09360. MS (ES)$^+$ *m/z* 301.1 [M + H]$^+$. HPLC t_R 3.9 min.

Synthesis of NBD-Bn-CHO. To a solution of compound **1** (301 mg, 1.0 mmol) in dry DCM (40 mL) was added DMP (508 mg, 1.2 mmol) and the reaction was stirred at room temperature under a N$_2$ atmosphere. The progress of reaction

Table 1 Results of Van-Green staining of ocular specimens and correlation with Gram stain and culture

S. no.	Sample type	Gram stain results	Identified culture	Van-Green results
1	Pus from lid abscess	GP cocci	*Staphylococcus aureus* (GP)	+++
2	Pus from lid abscess	GP cocci	*Staphylococcus aureus* (GP)	+++
3	Eviscerated material	GP cocci	*Staphylococcus aureus* (GP)	+++
4	Canalicular pus	Filamentous GP bacilli	*Actinomyces* spp (GP)	+++
5	Corneal scraping	GP cocci	*Streptococcus pneumoniae* (GP)	+++
6	Canalicular pus	Filamentous GP bacilli	*Actinomyces* spp (GP)	+++
			Klebsiella oxytoca (GN)	
7	Corneal scraping	GN bacilli	*Pseudomonas aeruginosa* (GN)	−
8	Corneal scraping	GP bacilli	*Corynebacterium amycolatum* (GP)	+++
			Corynebacterium urealyticum (GP)	
9	Scleral scraping	GP cocci	*Staphylococcus aureus* (GP)	+++
10	Eviscerated material	GN cocco bacilli	*Neisseria subflava* (GN)	+
11	Eviscerated material	GN bacilli	*Pseudomonas aeruginosa* (GN)	−
12	Pus from orbit	GP bacilli	*Bacillus cereus* (GP)	++
13	Corneal scraping	GN bacilli	*Pseudomonas aeruginosa* (GN)	−
14	Eviscerated material	GP cocci	*Streptococcus pneumoniae* (GP)	++
15	Aqueous humor	Gram variable cocci	*Streptococcus pyogenes* (GP)	+++

was monitored by TLC. After complete conversion, the reaction mixture was quenched with a 20% aqueous $Na_2S_2O_3$ solution (20 mL) and a saturated aqueous $NaHCO_3$ solution (80 mL). The mixture was stirred until the aqueous layer was clear, then it was extracted with CH_2Cl_2 (3 × 50 mL). The combined organic layers were dried over $MgSO_4$ and concentrated under reduced pressure and purified by silica gel chromatography (hexane : EtOAc, 1 : 2, v/v) (orange solid, 284 mg, yield 95%).

^{1}H NMR (500 MHz, DMF-d_7) δ ppm: 10.09 (s, 1H), 9.92 (s, 1H), 8.55 (d, J = 8.8 Hz, 1H), 7.97 (d, J = 8.2 Hz, 2H), 7.78 (d, J = 8.1 Hz, 2H), 6.51 (d, J = 8.7 Hz, 1H), 5.04 (s, 2H). ^{13}C NMR (125 MHz, DMF-d_7) δ ppm: 192.6, 145.4, 145.2, 144.7, 144.5, 137.6, 136.3, 130.1, 128.4, 122.7, 100.1, 46.9. MS (ES)$^+$ m/z 299.1 [M + H]$^+$. HRMS (ESI)$^+$ calcd for $C_{14}H_{11}N_4O_4$ [M + H]$^+$ m/z 299.07748 found m/z 299.07710. HPLC t_R 4.5 min. FT-IR v_{max} (cm^{-1}): 3227 (NH), 3099, 3033 (CH aryl), 2953, 2918 (CH alkyl), 2850 (CH benzaldehyde), 1672 (C=O), 1555 (NO).

Vancomycin-NBD conjugate Van-Green. The reductive amination was carried out following a procedure from the literature.[25] To a solution of NBD-CHO (89.4 mg, 0.3 mmol) in DMF (8.8 mL) was added vancomycin hydrochloride (217.4 mg, 0.15 mmol) and DIPEA (66 μL). The reaction mixture was stirred for 4 h at 55 °C, then it was cooled down to room temperature and a solution of $NaBH_3CN$ (17.6 mg, 0.28 mmol) in MeOH (1.76 mL) was added. TFA (66 μL) was finally added and the reaction mixture was stirred at room temperature for 2 h. The solvents were removed under reduced pressure, and the resulting solid washed with Et_2O (3 × 15 mL). The crude was purified by preparative RP-HPLC (C18, eluent H_2O/MeCN), and the fractions were freeze dried to give the title compound (orange powder, 125 mg, 48%).

HRMS (ESI)$^+$ calcd for $C_{80}H_{86}Cl_2N_{13}O_{27}$ [M + H]$^+$ m/z 1730.51277 found m/z 1730.51290.

HPLC $t_{R(Prep)}$ 7.97 min. $t_{R(analytical)}$ 5.36 min.

FT-IR v_{max} (cm^{-1}): 3280 (br, OH, NH), 3097 (CH aryl), 2984 (CH alkyl), 1668 (C=O), 1587 (NH), 1505 (NO).

Bacterial culture. Microbial cultures (*Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*) were grown from agar plates and incubated overnight at 37 °C in Luria Bertani liquid medium (10 mL) in a shaking incubator. The overnight cultures (mid-log phase) were centrifuged at 5000 rpm for 8 minutes and the pellet suspended in 1 mL of phosphate buffered saline (PBS), washed with PBS twice and made up in 1 mL of PBS. The probe was used at a working concentration of 5 μM in phosphate buffered saline (see ESI†). Images were captured using FITC filter of Nikon Eclipse Ni (Nikon, USA) microscope under 40× and 100× magnification.

Validation of the vancomycin–NBD probe on standard strains

Optimization of probe concentration. μ-Slide fifteen-well glass bottom confocal chambers (Ibidi) were coated with poly-D-lysine (0.1 mg mL^{-1} in PBS) for 20 minutes at 37 °C, after which the wells were washed with PBS. Forty μL of the *S. aureus* ATCC 29213 liquid culture (concentrations were adjusted to 0.5 × 10^9 cfu mL^{-1}) were added to the coated wells and incubated for 1 hour. The wells were washed with PBS and probe of concentrations 100, 50, 10, 5, 1 and 0.1 μM were added (30 μL). After an incubation period of 1 hour, the wells were washed to remove unbound probe, the slide was sealed and imaged on a Leica SP5 confocal microscope (excitation laser: 476 nm, 10%, HyD detector: 510–590 nm with gain 100, brightfield PMT trans-detector with 250 gain).

Specificity of the probe. In order to ascertain if the probe labelled across Gram-positive strains, a range of microorganisms, namely, *S. aureus* ATCC 25923, *Streptococcus pyogenes* (ATCC no. 12384), *Bacillus cereus* (ATCC 13061) were tested. To check the specificity, Gram negative *Escherichia coli* DH5α, *Escherichia coli* (ATCC no. 25922) and *Pseudomonas aeruginosa* (ATCC 27853) were used. The slides were observed under FITC filters (Leica SP5 confocal and a Nikon Eclipse Ni microscopes). A mixture of *S. aureus* (Gram positive bacteria) and *E. coli* (Gram negative bacteria) were prepared by adding equal volumes of saline suspensions of both strains, followed by labelling with the Van-Green probe.

Paper

Fig. 4 Representative bright-field and fluorescent images of ocular specimens following Gram staining and Van-Green labelling. (a) A corneal scraping stained by Gram stain showing Gram positive cocci (left) that grew *S. aureus*, with Van-Green staining fluorescent coccal forms (right). (b) Corneal scraping showing Gram negative bacilli (left) that grew *P. aeruginosa* with negative Van-Green staining. (c) An aqueous aspirate showing Gram variable bacilli (left) that grew *Streptococcus* spp and fluorescent coccal forms with Van-Green staining. (d) The comparison of fluorescence intensity (5 μM Van-Green) for target and non-target species found in clinical samples as calculated by ImageJ, Fiji.

For quantification images were analyzed by Image J (Fiji, National Institutes of Health). For analysis, an average intensity of 25 labelled bacteria distributed over the area of interest were analysed (an average of 10 dark spots was taken as the background). The corrected intensity was calculated by subtracting the product of the mean area and the mean intensity of the background from the integrated density of the labelled cells. In order to determine if Van-Green was able to permeabilise the bacteria we performed live-dead staining experiments (LIVE/DEAD BacLight Bacterial Viability Kit, ThermoFisher Scientific) and viewed the bacteria under a fluorescent microscope using FITC filters.

Determination of antibacterial activity of the probe. The MIC of Van-Green and the parent compound vancomycin was determined using a broth microdilution method against standard strains, namely *Staphylococcus aureus* (ATCC no. 25923) and *Escherichia coli* (ATCC no. 25922) according to the CLSI guidelines. Briefly, bacteria were cultured in Muller Hinton broth (MHB) (Himedia) at 37 °C overnight, after which the cell density was standardized to match 0.5 McFarland standard (1.5×10^8 CFU mL^{-1}). The compounds were serially diluted two-fold across the wells, with concentrations ranging from 256 μM to 0.25 μM plated in duplicate. The mid-log phase cultures of bacteria were diluted to the final concentration of 5×10^5 CFU mL^{-1} after which 100 μL of bacterial suspension was added to 100 μL of medium containing various concentrations of the compounds in a 96-well plate. Controls included growth control and a broth control. All the plates were covered and incubated at 37 °C for 18–24 h with the MIC defined as the lowest compound concentration at which no bacterial growth was visible.

Validation of the Van-Green probe using clinical specimens

Conventional microbiological investigations. The ocular specimens were processed immediately after receipt at the laboratory for conventional microbiological investigations. Smears were made for Gram staining using a 10% KOH/calcofluor white wet mount. The specimens were inoculated into the following solid media (5% sheep blood agar (BA), Brucella blood agar (BBA), chocolate agar (CA), MacConkey agar (MAC) and Sabouraud's dextrose agar (SDA)) and liquid media (brain heart infusion broth (BHIB) and thioglycolate broth). Once bacteria or fungi were isolated, the isolates were identified by standard procedures including colony morphology and biochemical tests. When significant pathogens were grown, fresh isolates were identified using GN/GP/NH cards from the VITEK 2®system (BioMérieux, France).

Labelling by Van-Green. A total of 15 Gram stain positive ocular samples were used for the study. 5 μM was the standardized concentration of the probe used for analysis of the clinical specimens. A total of 20 μL of 5 μM Van-Green was added directly to the methanol fixed slides. A coverslip was mounted on the smear and fluorescent imaging was done immediately. Images were captured using a camera fixed to the fluorescent microscope. The results were compared with the Gram stain and conventional culture results.

Conclusions

Conjugation of the fluorophore NBD to the antibacterial agent vancomycin gave a fluorescent probe that was able to efficiently label Gram positive clinical pathogens with excellent sensitivity and specificity. The probe showed excellent Gram specificity, and did not label Gram negative pathogens. This green-emitting probe constitutes a reliable, convenient and versatile diagnostic tool. As the "green channel" is the most common fluorescent wavelength found in standard microscope systems, with other wavelengths

often limited, the optical properties of Van-Green make it usable on standard equipment, across different laboratories and facilities. Additionally, the solvato-fluorogenicity of the NBD dye switches "on" the emission specifically in the hydrophobic cell membrane of the target pathogen, without causing significant background signal in the usual aqueous environment of clinical samples. The probe therefore showed bright fluorescence, with negligible background, for multiple clinical ocular specimens under practical, wash-free, conditions. This easily synthesized, selective fluorescent probe allows the rapid and accurate diagnosis of Gram-positive microbes that dominate bacterial eye infections, thereby enabling early follow-up treatment.

Author contributions

Richa Sharma: data curation, formal analysis, investigation, methodology, validation, visualization, writing – original draft, writing – review & editing. Harinee Rajagopalan: formal analysis, investigation, validation, visualization. Maxime Klausen: data curation, formal analysis, investigation, methodology, visualization, writing – original draft, writing – review & editing. Mani Vimalin Jeyalatha: formal analysis, investigation, validation, visualization. Muhammed Üçüncü: data curation, formal analysis, investigation, methodology, validation, visualization, writing – review & editing. Seshasailam Venkateswaran: conceptualization, supervision, visualization, writing – review & editing. Appakkudal R. Anand: data curation, formal analysis, investigation, methodology, validation, visualization, writing – original draft, writing – review & editing. Mark Bradley: conceptualization, funding acquisition, methodology, project administration, resources, supervision, visualization, writing – review & editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Notes and references

1 M. Teweldemedhin, H. Gebreyesus and A. H. Atsbaha, *et al.*, Bacterial profile of ocular infections: a systematic review, *BMC Ophthalmol.*, 2017, **17**, 212.

2 D. S. J. Ting, C. S. Ho, R. Deshmukh, D. G. Said and H. S. Dua, *Eye*, 2021, **35**, 1084–1101.

3 M. van Oosten, M. Hahn, L. M. Crane, R. G. Pleijhuis, K. P. Francis, J. M. van Dijl and G. M. van Dam, *FEMS Microbiol. Rev.*, 2015, **39**, 892–916.

4 L. Miao, W. Liu, Q. Qiao, X. Li and Z. Xu, *J. Pharm. Anal.*, 2020, **10**, 444–451.

5 M. R. L. Stone, M. S. Butler, W. Phetsang, M. A. Cooper and M. A. T. Blaskovich, *Trends Biotechnol.*, 2018, **36**, 523–536.

6 A. Baibek, M. Üçüncü, E. A. Blackburn, M. Bradley and A. Lilienkampf, *Pept. Sci.*, 2021, **113**, e24167.

7 H.-Y. Kwon, X. Liu, E. G. Choi, J. Y. Lee, S.-Y. Choi, J.-Y. Kim, L. Wang, S.-J. Park, B. Kim, Y.-A. Lee, J.-J. Kim, N. Y. Kang and Y.-T. Chang, *Angew. Chem., Int. Ed.*, 2019, **58**, 8426–8431.

8 S. Kang, Y. Jung, J. Jung, K.-H. Park and D. Kim, *Dyes Pigm.*, 2021, **185**, 108939.

9 X. Liu, Z. Yang, W. Xu, Y. Chu, J. Yang, Y. Yan, Y. Hu, Y. Wang and J. Hua, *J. Mater. Chem. C*, 2019, **7**, 12509–12517.

10 P. Bao, C. Li, H. Ou, S. Ji, Y. Chen, J. Gao, X. Yue, J. Shen and D. Ding, *Biomater. Sci.*, 2021, **9**, 437–442.

11 S. M. Sayed, K.-F. Xu, H.-R. Jia, F.-F. Yin, L. Ma, X. Zhang, A. Khan, Q. Ma, F.-G. Wu and X. Lu, *Anal. Chim. Acta*, 2021, **1146**, 41–52.

12 T. Gao, X. Cao, J. Dong, Y. Liu, W. Lv, C. Li, X. Feng and W. Zeng, *Dyes Pigm.*, 2017, **143**, 436–443.

13 M. van Oosten, T. Schäfer, J. A. C. Gazendam, K. Ohlsen, E. Tsompanidou, M. C. de Goffau, H. J. M. Harmsen, L. M. A. Crane, E. Lim, K. P. Francis, L. Cheung, M. Olive, V. Ntziachristos, J. M. van Dijl and G. M. van Dam, *Nat. Commun.*, 2013, **4**, 2584.

14 A. R. Akram, S. V. Chankeshwara, E. Scholefield, T. Aslam, N. McDonald, A. Megia-Fernandez, A. Marshall, B. Mills, N. Avlonitis, T. H. Craven, A. M. Smyth, D. S. Collie, C. Gray, N. Hirani, A. T. Hill, J. R. Govan, T. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, *Sci. Transl. Med.*, 2018, **10**, eaal0033.

15 A. Baibek, M. Üçüncü, B. Short, G. Ramage, A. Lilienkampf and M. Bradley, *Chem. Commun.*, 2021, **57**, 1899–1902.

16 A. Megia-Fernandez, M. Klausen, B. Mills, G. E. Brown, H. McEwan, N. Finlayson, K. Dhaliwal and M. Bradley, *Chemosensors*, 2021, **9**, 117.

17 A. Labbé, C. Khammari, B. Dupas, E. Gabison, E. Brasnu, M. Labetoulle and C. Baudouin, *Ocul. Surf.*, 2009, **7**, 41–52.

18 Y. E. Wang, T. C. Tepelus, L. A. Vickers, E. Baghdasaryan, W. Gui, P. Huang, J. A. Irvine, S. Sadda, H. Y. Hsu and O. L. Lee, *Int. Ophthalmol.*, 2019, **39**, 2865–2874.

19 R. D. Cooper, N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. L. Mullen, T. F. Butler, M. J. Rodriguez, B. E. Huff and R. C. Thompson, *J. Antibiot.*, 1996, **49**, 575–581.

20 D. Guan, F. Chen, L. Xiong, F. Tang, Y. Faridoon, N. Qiu, L. Zhang, J. Gong, L. Lan Li and W. Huang, *J. Med. Chem.*, 2018, **61**, 286–304.

21 A. Okano, A. Nakayama, A. W. Schammel and D. L. Boger, *J. Am. Chem. Soc.*, 2014, **136**(39), 13522–13525.

22 S. J. Kim, K. S. E. Tanaka, E. Dietrich, A. Rafai Far and J. Schaefer, *Biochemistry*, 2013, **52**, 3405–3414.

23 S. N. Leonard and M. J. Rybak, *Pharmacotherapy*, 2008, **28**, 458–468.

24 A. S. Klymchenko and Y. Mely, in *Progress in Molecular Biology and Translational Science*, ed. M. C. Morris, Academic Press, 2013, vol. 113, pp. 35–58.

25 D. Guan, F. Chen, L. Xiong, F. Tang, F. Faridoon, Y. Qiu, N. Zhang, L. Gong, J. Li, L. Lan and W. Huang, *J. Med. Chem.*, 2017, **61**, 286–304.